ERBB3 and breast carcinoma: This was accompanied by cellular viability deficits in MCF7, MCF7-JAM+ and SK-BR-3 breast cancer cells (Figure 2c; p < 0.01, p < 0.01 and p < 0.001 respectively for JAM-A silencing; p < 0.001, p < 0.01 and p < 0.001 respectively for HER3 silencing).